New bioengineered strategy shows potential for treating ulcerative colitis

By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.

Single dose of MVA-BN vaccine offers 58% protection against mpox

Researchers confirm the effectiveness of the modified vaccinia Ankara-Bavarian Nordic vaccine against mpox.

September 16, 2024

Kronos stops work on leukemia drug; Aldeyra shares rally on eczema data; Atavistik Bio’s $40M

Kronos Bio stops blood cancer program: The biotech on Monday said Phase Ib data of lanraplenib in a mutated subset of acute myeloid leukemia patients

December 20, 2023

Everest Medicines receives NMPA approval for IgAN therapy

Share this article China’s NMPA has approved Nefecon to treat primary immunoglobulin A nephropathy in adult patients. Credit: Pixel-Shot / Shutterstock.com. Everest Medicines has received

November 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.